title: Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio".
authors.forename: Paolo
authors.initials: P
authors.lastname: Mulatero
authors.forename: Alberto
authors.initials: A
authors.lastname: Milan
authors.forename: Franco
authors.initials: F
authors.lastname: Veglio
mesh_terms: D000450:Aldosterone / Q000097:blood*; D000584:Amiloride / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001539:Bendroflumethiazide / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D049993:Sodium Chloride Symporter Inhibitors; D013148:Spironolactone; D000450:Aldosterone; D001539:Bendroflumethiazide; D000584:Amiloride; D019808:Losartan